News
Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...
Zacks Investment Research on MSN2d
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesFor the quarter ended March 2025, Exelixis (EXEL) reported revenue of $555.45 million, up 30.6% over the same period last year. EPS came in at $0.62, compared to $0.17 in the year-ago quarter.The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback